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Abstract 
 
Purpose: Until now, no study has evaluated CXCL9 in HCV-related mixed 
cryoglobulinemia (MC) patients in presence/absence of autoimmune thyroiditis (AT).  
Methods: Serum CXCL9 and CXCL10 have been measured in 60 patients with MC 
(MCo), in 35 patients with MC and AT (MC-AT),  in sex and age-matched controls: 60 
healthy (Control 1); 35 patients with AT without cryoglobulinemia (Control 2).  
Results: CXCL9 and CXCL10 were higher in MC-AT patients than Control 2 
(p<0.0001) and MCo (p=0.01), in MCo than Control 1 (p<0.0001) and in Control 2 than 
Control 1 (p<0.001). By defining a high CXCL9 level as a value >2 SD above the mean 
value of the Control 1 (>122 pg/mL), 5% of Control 1, 34% of Control 2, 91% of MCo 
and 97% of MC+AT, had high CXCL9 (p<0.0001, Chi-Square). By simple regression 
analysis CXCL9 and CXCL10 were related to each other in MCo (r=0.426, p=0.001) and 
in MC-AT (r=0.375, p=0.001). 
Conclusions: We first demonstrate high serum levels of CXCL9 in cryoglobulinaemic 
patients, especially with AT. Furthermore, a strong association between serum CXCL9 
and CXCL10 has been observed in patients with MC in presence/absence of AT.  
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Introduction 
 
Monokine induced by interferon (IFN)-gamma (MIG)/chemokine (CXC motif) ligand 
(CXCL)9 and IFN-gamma-induced protein 10 (IP-10/CXCL10) are members of the Glu-
Leu-Arg (the ELR motif) CXC chemokine subfamily, that recruits activated lymphocytes 
via CXCR3 receptor (Liao F and others 1995). Expression of CXCL9 is induced by IFN-
gamma (the prototypical Th1 cytokine) and is strongly enhanced in presence of tumor 
necrosis factor-alpha (TNF)-alpha in different cells and tissues (Lacotte S and others 
2009). CXCL9 has been implicated in pathologies characterized by the accumulation of 
activated Th1 lymphocytes.  
Recent evidence has shown that CXC alpha-chemokines (Th1), especially CXCL10, have 
a key role in mixed cryoglobulinemia (MC), in particular in MC patients with active 
vasculitis (Antonelli A and others 2008a). 
Moreover, CXCL10 has an important role in the initial phases of autoimmune thyroiditis 
(AT), as it is elevated in patients with newly diagnosed AT, especially in the presence of 
a more aggressive thyroiditis and hypothyroidism (Antonelli A and others 2004a). 
We have previously demonstrated that autoimmune thyroid disorders are frequently 
present in cryoglobulinaemic patients (Antonelli A and others 2004b). Furthermore, it has 
been suggested that the basis of this association could be linked to the activation of a Th1 
immune response, as high levels of the Th1 CXCL10 chemokine are present both in 
patients with MC-AT such as in patients with MC alone (Antonelli A and others 2008b, 
Antonelli A and others 2008c). 
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To our knowledge, CXCL9 has not been evaluated in patients with MC (and vasculitis), 
while few studies have suggested the involvement of CXCL9 in AT (Kimura H and 
others 2004, Antonelli A and others 2009a, Antonelli A and others 2009b, Antonelli A 
and others 2010a, Antonelli A and others 2011a, Antonelli A and others 2011b). 
Therefore, in this study we measured serum CXCL9 levels, in comparison with CXCL10, 
in a large sample of cryoglobulinaemic patients with/without AT, respect to normal 
controls. 
  
Materials and Methods 
 
Patients with MC without AT (MCo) 
Sixty MC patients were recruited into the study, who consecutively referred to the 
Rheumatology Unit of the University of Modena. The diagnosis of MC was done 
evaluating the presence of a specific core-set of clinical and laboratory parameters, and 
the presence of serum mixed (IgG-IgM) cryoglobulins (Ferri C and others 2002, Ferri C 
2008). HCV infection was systematically evaluated in all patients (HCV-negative 
patients were excluded). MC+HCV subjects without liver cirrhosis (by histology, 
laboratory evidence of liver damage and/or ultrasound-proven portal hypertension) 
(Antonelli A and others 2004c, Antonelli A and others 2005) and without hepatocellular 
carcinoma, and in whom the presence of associated thyroid autoimmune disorders were 
excluded [after a thyroid screening evaluating history, physical examination, thyroid 
stimulating hormone (TSH), free triiodo-thyronine (FT3), free thyroxine (FT4), anti-
thyroglobulin (AbTg) and anti-thyroid peroxidase (AbTPO) antibodies measurements, 
and ultrasonography], were included in this group. 
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Table 1 reports the main demographic and clinico-serological features of MC patients. 
Among them, 25 had been previously treated with IFN-alpha [average 6.5 months (range 
1-12), mean dosage 11 MU/week (range 3-7); time elapsed from the last IFN-alpha 
treatment 4-75 months (mean 39)]. No statistically significant difference was observed in 
the main demographic and clinico-serological features of MC patients treated or 
untreated with IFN-alpha. 
Forty-two MC patients were taking corticosteroids (≤ 5 mg/day of prednisone 
equivalents) during the study, while 5 had previously been treated and 13 had never been 
treated.  No MC patient had had plasma exchange treatment in the last year before the 
study. The presence of Raynaud's phenomenon, secondary Sjogren's syndrome, skin 
ulcers, peripheral neuropathy, and renal and liver involvement in MC patients was 
evaluated as previously described (Ferri C and others 2002, Ferri C 2008), such as routine 
blood chemistry (Antonelli A and others 2004b). 
Patients with MC and AT (MC-AT) 
Thirty-five MC patients were recruited into the study, who consecutively referred to the 
Rheumatology Unit of the University of Modena and in whom a thyroid screening  (see 
above) revealed the presence of thyroid autoimmune disorders. 
Table 1 reports the main demographic and clinico-serological features of MC patients. 
Among them, 12 had been previously treated with IFN-alpha [average 5.4 months (range 
1-13); mean dosage 10 MU/week (range 3-7); time elapsed from the last course of IFN-
alpha treatment 3-76 months (mean 41)]. No statistically significant difference was 
observed in the main demographic and clinico-serological features of MC patients treated 
or untreated with IFN-alpha. 
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Twenty-six MC patients were taking corticosteroids (≤ 5 mg/day of prednisone 
equivalents) during the study, 3 had been previously treated and 6 had never been treated. 
No MC-AT patients had had plasma exchange treatment in the last year before the study.  
Controls  
Two control groups were evaluated, who were extracted from a random sample of the 
general population from the same geographic area (Antonelli A and others 2005), coupled 
by sex and age with MC patients, without HCV infection or other liver disorders. 
Control 1 involved 50 subjects (41 females, 9 males; age, 60 ± 11 years), in whom a 
complete thyroid screening excluded the presence of thyroid or autoimmune disorders, or 
any kind of immunomodulant therapy.  
Control 2 consisted of 40 subjects (33 females, 7 males; age, 61 ± 12 years), in whom a 
complete thyroid screening demonstrated the presence of thyroid autoimmune disorders, 
but excluded the presence of other autoimmune disorders and any kind of 
immunomodulant therapy.  
A blood sample was collected in the morning in all patients and controls, after overnight 
fasting.  
Informed consent was obtained from all patients and controls, and the study was approved 
by the local Ethical Committee.  
Laboratory  studies 
Cryocrit, cryoglobulin composition, C3-C4 fractions were measured as previously 
described (Ferri C 2008, Antonelli A and others 2012); anti-nuclear (ANA), anti-smooth 
muscle (ASMA), and anti-mitochondrial (AMA) autoantibodies were detected by current 
techniques (Ferri C 2008, Antonelli A and others 2012). Sera with a titer > 1:80 were 
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considered positive. Anti-extractable nuclear antigen (ENA) antibodies, including anti-
Scl70, anti-Sm, -RNP, -SSA/SSB, -PCNA, -SL and -Jo1 specificities, were detected by 
counter-immunoelectrophoresis (Antonelli A and others 2004b, Antonelli A and others 
2012, Antonelli A and others 2009c). 
Anti-HCV antibodies and HCV RNA were determined as previously reported (Ferri C 
and others 1993, Zignego AL and others 1990, Antonelli A and others 2012).  
Thyroid evaluation, thyroid blood flow, FT3, FT4, TSH, AbTPO, AbTg determination, 
were performed as previously described (Antonelli A and others 2004a). 
Circulating CXCL9 levels were measured by a quantitative sandwich immunoassay 
commercially available kit (R&D Systems, Inc., Minneapolis, MN, USA; sensitivity 1.1-
10.2 pg/; mean minimum detectable dose 3.2 pg/mL; intra- and inter-assay coefficients of 
variation 4.0% and 7.1%). 
Circulating CXCL10 levels were measured by a quantitative sandwich immunoassay 
commercially available kit (R&D Systems; sensitivity 0.40-4.51 pg/mL; mean minimum 
detectable dose 1.71 pg/mL; intra- and inter-assay coefficients of variation 2.9% and 
6.4%). 
Data analysis  
Normally distributed variables are given as mean±SD, otherwise as median and 
[interquartile range]. One-way analysis of variance (ANOVA) for normally distributed 
variables were used to compare mean group values, otherwise by the Mann-Whitney U or 
Kruskal-Wallis test. Chi-Square test was used to compare proportions. Bonferroni-Dunn 
test was used for Post-hoc comparisons on normally distributed variables. Univariate and 
multivariate analysis were performed by simple or multiple linear regression analysis. 
Statistical power (ex post analysis; stat-power) was calculated. 
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Results 
 
The clinical phenotype of cryoglobulinemia was not significantly different in MCo and 
MC-AT patients (Table 1). The demographic and clinical thyroid features of patients and 
controls are reported in Table 2. MC-AT patients and Control 2 showed significantly 
higher thyroid autoantibodies levels, hypoechogenicity and hypervascularity of the 
thyroid gland, and subclinical hypothyroidism, with respect  to Control 1 and MCo.  
CXCL9 
Serum CXCL9 levels were significantly (Table 2) higher in Control 2 than Control 1 
(p<0.001) and in MCo than Control 1 (p<0.0001; stat-power =1) (Fig. 1a). MC-AT 
patients have circulating CXCL9 levels significantly higher than Control 2 (p<0.0001; 
stat-power =1) (Fig. 1b), and than MC (p=0.01; stat-power=0.9). In MCo and MC-AT 
patients serum CXCL9 levels were not associated with any of the clinical features of 
cryoglobulinemia; for example: a) CM-II or CM-III status: 398 ± 164 versus 372 ± 151 in 
MCo; 478 ± 234 versus 503 ± 191 in MC-AT; b) HCV viral load (<1,000,000 versus 
>1,000,000): 404 ± 171 versus 369 ± 148 in MCo; 486 ± 207 versus 498 ± 217 in MC-
AT; c) previous treatment with IFN, yes versus no; 396 ± 163 versus 377 ± 143 in MCo; 
497 ± 222 versus 484 ± 206 in MC-AT; d) treatment with corticosteroids, yes versus 
never treated with corticosteroids; 358 ± 171 versus 387 ± 156 in MCo; 469 ± 221 versus 
489 ± 234 in MC-AT. 
In MC-AT patients and Control 2, CXCL9 was studied in relation to the clinical features 
of AT (age; gender; thyroid volume < 6 mL; thyroid hypoechoic pattern, or 
hypervascularity; AbTg or AbTPO positivity; subclinical hypothyroidism). Serum 
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CXCL9 levels were significantly increased in MC-AT patients with hypothyroidism with 
respect to those without hypothyroidism (615 ± 321 versus 415 ± 187; p=0.04, ANOVA), 
and in Control 2 with a thyroid hypoechoic pattern with respect to those without a 
hypoechoic pattern (187 ± 134 versus 122 ± 119; p=0.03, ANOVA).  
By defining a high CXCL9 level as a value of at least 2 SD above the mean value of the 
control group 1 (>122 pg/mL), 5% of Control 1, 34% of Control 2, 91% of MCo and 
97% of MC-AT, had high CXCL9 (p<0.0001, Chi-Square).  
No significant association was observed in relation to the duration of the disease. 
CXCL10 
Serum CXCL10 levels were significantly (Table 2) higher in Control 2 than in Control 1 
(p<0.001). MCo have serum CXCL10 levels significantly higher than Control 1 
(p<0.0001) (Fig. 2a). MC-AT patients have serum CXCL10 levels higher than Control 2 
(p<0.0001) (Fig. 2b), and than MCo (p=0.01). In MCo and MC-AT patients, circulating 
CXCL10 levels were not associated with any of the clinical features of cryoglobulinemia; 
for example: a) CM-II or CM-III status: 302 ± 176 versus 319 ± 159 in MCo; 399 ± 167 
versus 384 ± 202 in MC-AT; b) HCV viral load (<1,000,000 versus >1,000,000): 310 ± 
146 versus 318 ± 178 in MCo; 408 ± 212 versus 376 ± 174 in MC-AT; c) previous 
treatment with IFN, yes versus no; 321 ± 178 versus 305 ± 144 in MCo; 373 ± 170 versus 
398 ± 214 in MC-AT; d) treatment with corticosteroids, yes versus never treated with 
corticosteroids; 309 ± 167 versus 334 ± 161 in MCo; 392 ± 193 versus 384 ± 191 in MC-
AT. 
In MC-AT patients and control 2, CXCL10 was studied in relation to the clinical features 
of AT (see above). Serum CXCL10 levels were significantly increased in MC-AT 
patients with a thyroid hypoechoic pattern versus the ones without a hypoechoic pattern 
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(412 ± 156 versus 301 ± 176; p=0.02, ANOVA) and hypothyroidism (387 ± 145 versus 
309 ± 123; p=0.03, ANOVA), and in Control 2 with a thyroid hypoechoic pattern versus 
the ones without a hypoechoic pattern (111 ± 131 versus 187 ± 124; p=0.04, ANOVA). 
By defining a high CXCL10 level as a value of at least 2 SD above the mean value of the 
control group (>188 pg/mL), 5% of Control 1, 24% of Control 2, 51% of MCo and 83% 
of MC-AT, had high CXCL10 (p<0.0001, Chi-Square).  
No significant association was observed in relation to the duration of the disease.  
CXCL9 versus CXCL10 
CXCL9 and CXCL10 were related to each other in MCo (r=0.426, p=0.001), and in MC-
AT patients (r=0.375, p=0.001), by simple regression analysis. 
 
Discussion 
 
Our study first demonstrates high circulating levels of CXCL9 in MC patients, especially 
with autoimmune thyroiditis and hypothyroidism. CXCL10 levels of MC-AT patients 
were significantly higher than those of MCo patients. Furthermore, a strong association 
between serum CXCL9 and CXCL10 has been observed in patients with MC 
with/without AT. 
The data regarding high level of CXCL9 in MC patients agree with the results obtained in 
patients with HCV chronic infection; in fact, most of the studies showed high serum 
levels of CXCL9 in HCV chronic infection (Butera D and others 2005, Wasmuth HE and 
others 2009, Zeremiski M and others 2009, Moura AS and others 2010, Wan L and others 
2009). Only one study did not show any significant difference with controls (Helbig KJ 
and others 2009). 
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Moreover, it has been evidenced that the most relevant changes in gene expression of 
HCV patients with first stage of liver fibrosis were mainly associated with the 
transcriptional network regulated by IFNs, including IFN-gamma-inducible genes 
(CXCL9, CXCL10, CXCL11) (Bièche I and others 2005). Moreover, circulating levels of 
CXCL9, sTNFR1, and sTNFR2 were associated with liver histology, suggesting a role of 
TNF activation and Th1-type cell-mediated immune response in the pathogenesis of 
HCV infection (Moura AS and others 2010).  
These results suggest CXCL9 is produced by hepatocytes in the HCV-infected liver and 
is involved in T cell recruitment and in the pathogenesis of HCV chronic hepatitis 
infection.  
In this respect, only patients without cirrhosis were recruited in the study, while the role 
of thyroid autoimmune disorders (that may influence CXCL9 serum levels) was 
specifically considered. Our study demonstrates high circulating CXCL9 in MC patients, 
at levels similar to those found in HCV chronic infection without cirrhosis, and suggests 
that CXCL9 is mainly sustained by the HCV chronic hepatitis in MC patients (Butera D 
and others 2005, Wasmuth HE and others 2009, Zeremiski M and others 2009, Moura AS 
and others 2010, Wan L and others 2009). 
Previous our works demonstrated a correlation between CXCL10 and CXCL11 serum 
levels and presence of skin vasculitis (Antonelli A and others 2008a, Antonelli A and 
others 2011c); consequently, we expected to find a correlation also with CXCL9. In fact, 
these 3 chemokines, which belong to the same CXC chemokines subfamily, are induced 
by IFN-gamma, recruit T cells, and bind the CXCR3 receptor; consistently, we find that 
CXCL10 and CXCL9 were related to each other in a simple regression analysis (see 
Results). 
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MC-AT have significantly higher circulating CXCL9 than MCo patients. This suggests 
the further increase of serum CXCL10 levels may be due to the thyroiditis itself 
(Antonelli A and others 2008d), and to a predominance of the Th1 immune response in 
MC patients with AT (Antonelli A and others 2010b). 
In agreement with these data, recent results show higher CXCL9 serum levels in AT 
patients with respect to healthy controls (Antonelli A and others 2011a, Antonelli A and 
others 2011b). Furthermore, Kimura et al. (Kimura H and others 2004) analyzed C57BL6 
transgenic mice that aberrantly express IFN-gamma under control of the thyroglobulin 
promoter (Antonelli A and others 2012). Transgenics exclusively expressed CCL4, 
CXCL9, and CXCL11, and showed increased expression of CCL5 and CXCL10. 
Furthermore, the secretion of CXCL9 in primary cultures of human thyrocytes can be 
stimulated by IFN-gamma and TNF-alpha (Antonelli A and others 2009a, Antonelli A 
and others 2009b, Antonelli A and others 2010a). Only one study showed discrepant 
results in a small number of patients with autoimmune thyroiditis (Domberg J and others 
2008). 
To our knowledge, this is the first study reporting a correlation between CXCL9 and 
CXCL10 levels in MC patients with/without AT. This correlation strongly reinforces the 
hypothesis that the immune process in chronic hepatitis C and AT (a Th1 immune 
response with secretion of IFN-gamma and TNF-alpha) might be responsible of the 
increase of both chemokines both in MC and AT. However, CXCL9 has some 
peculiarities with respect to CXCL10 (Loetscher P and others 2001, Antonelli A and 
others 2011b), suggesting that they may have, at least in part, a different role in MC and 
AT, that remains to be investigated. 
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More recently, it has been shown the high plasma CXCL10 levels correlate with a poor 
outcome of antiviral therapy in patients with hepatitis C (Antonelli A and others 2009d, 
Antonelli A and others 2012); a low baseline CXCL10 level was associated with low 
viral load, rapid viral response, and a sustained viral response in HCV+ patients  treated 
with IFN (Butera D and others 2005, Lagging M and others 2006, Romero AI and others 
2006, Diago M and others 2006). Since IFN is an effective therapy for MC, future studies 
will evaluate if pre-treatment serum CXCL9 levels may be associated with virological 
response to IFN in MC patients (Antonelli A and others 2012).  
In conclusion, we first demonstrate high serum levels of CXCL9 in MC patients. Serum 
CXCL9 levels in MC-AT patients are significantly higher than in MCo patients. 
Furthermore, a strong association between serum CXCL9 and CXCL10 has been 
observed in patients with MC with/without AT, strongly suggesting the importance of a 
Th1 immune response in the pathogenesis of both diseases. Future studies in larger series 
of patients will be done in order to evaluate the usefulness of serum CXCL9 dosage as 
prognostic marker in the follow-up of MC patients, especially with AT. 
 
 
 Antonelli A and others 
 
 14 
References 
 
Antonelli A, Ferri C, Fallahi P, Ferrari SM, Sebastiani M, Ferrari D, Giunti M, Frascerra 
S, Tolari S, Franzoni F, Galetta F, Marchi S, Ferrannini E. 2008a. High values of 
CXCL10 serum levels in mixed cryoglobulinemia associated with hepatitis C infection. 
Am J Gastroenterol 103:2488-2494.  
Antonelli A, Rotondi M, Fallahi P, Romagnani P, Ferrari SM, Buonamano A, Ferrannini 
E, Serio M. 2004a. High levels of circulating CXCL10 are associated with chronic 
autoimmune thyroiditis and hypothyroidism. J Clin Endocrinol Metab 89:5496-5499. 
Antonelli A, Ferri C, Fallahi P, Giuggioli D, Nesti C, Longobardo G, Fadda P, Pampana 
A, Maccheroni M, Ferrannini E. 2004b. Thyroid involvement in patients with overt 
HCV-related mixed cryoglobulinaemia. QJM 97:499-506. 
Antonelli A, Ferri C, Fallahi P, Ferrari SM, Frascerra S, Carpi A, Nicolini A, Ferrannini 
E. 2008b. Alpha-chemokine CXCL10 and beta-chemokine CCL2 serum levels in patients 
with hepatitis C-associated cryoglobulinemia in the presence or absence of autoimmune 
thyroiditis. Metabolism 57:1270-1277. 
Antonelli A, Ferri C, Fallahi P, Ferrari SM, Frascerra S, Sebastiani M, Franzoni F, 
Galetta F, Ferrannini E. 2008c. High values of CXCL10 serum levels in patients with 
hepatitis C associated mixed cryoglobulinemia in presence or absence of autoimmune 
thyroiditis. Cytokine 42:137-143. 
Antonelli A, Ferrari SM, Fallahi P, Frascerra S, Santini E, Franceschini SS, Ferrannini E. 
2009a. Monokine induced by interferon gamma (IFNgamma) (CXCL9) and IFNgamma 
inducible T-cell alpha-chemoattractant (CXCL11) involvement in Graves' disease and 
 Antonelli A and others 
 
 15 
ophthalmopathy: modulation by peroxisome proliferator-activated receptor-gamma 
agonists. J Clin Endocrinol Metab 94:1803-1809.  
Antonelli A, Ferri C, Ferrari SM, Colaci M, Sansonno D, Fallahi P. 2009b. Endocrine 
manifestations of hepatitis C virus infection. Nature Clinical Practice Endocrinology & 
Metabolism 5:26-34. 
Antonelli A, Ferrari SM, Fallahi P, Ghiri E, Crescioli C, Romagnani P, Vitti P, Serio M, 
Ferrannini E. 2010a. Interferon-alpha, -beta and -gamma induce CXCL9 and CXCL10 
secretion by human thyrocytes: modulation by peroxisome proliferator-activated 
receptor-gamma agonists. Cytokine 50:260-267. 
Antonelli A, Ferrari SM, Frascerra S, Di Domenicantonio A, Nicolini A, Ferrari P, 
Ferrannini E, Fallahi P. 2011a. Increase of Circulating CXCL9 and CXCL11 Associated 
with Euthyroid or Subclinically Hypothyroid Autoimmune Thyroiditis. J Clin Endocrinol 
Metab 96:1859-1863. 
Antonelli A, Ferrari SM, Frascerra S, Galetta F, Franzoni F, Corrado A, Miccoli M, 
Benvenga S, Paolicchi A, Ferrannini E, Fallahi P. 2011b. Circulating chemokine (CXC 
motif) ligand (CXCL)9 is increased in aggressive chronic autoimmune thyroiditis, in 
association with CXCL10. Cytokine 55:288-293. 
Antonelli A, Ferri C, Fallahi P, Sebastiani M, Nesti C, Barani L, Barale R, Ferrannini E. 
2004c. Type 2 diabetes in hepatitis C-related mixed cryoglobulinaemia patients. 
Rheumatology 43:238-240. 
Antonelli A, Ferri C, Fallahi P, Pampana A, Ferrari SM, Goglia F, Ferrannini E.  2005. 
Hepatitis C virus infection: evidence for an association with type 2 diabetes. Diabetes 
Care 28:2548-2550. 
 Antonelli A and others 
 
 16 
Antonelli A, Fallahi P, Ferrari SM, Sebastiani M, Manfredi A, Mazzi V, Fabiani S, 
Centanni M, Marchi S, Ferri C. 2012. Circulating CXCL11 and CXCL10 are increased in 
hepatitis C-associated cryoglobulinemia in the presence of autoimmune thyroiditis. Mod 
Rheumatol 22:659-667.  
Antonelli A, Ferri C, Fallahi P, Ferrari SM, Frascerra S, Franzoni F, Galetta F, Zignego 
AL, Ferrannini E. 2009c. CXCL10 and CCL2 serum levels in patients with mixed 
cryoglobulinaemia and hepatitis C. Dig Liver Dis 41:42-48.  
Antonelli A, Ferri C, Ferrari SM, Ruffilli I, Colaci M, Frascerra S, Miccoli M, Franzoni 
F, Galetta F, Fallahi P. 2011c. High Serum Levels of CXCL11 in Mixed 
Cryoglobulinemia Are Associated with Increased Circulating Levels of Interferon-
{gamma}. J Rheumatol 38:1947-1952. 
Antonelli A, Fallahi P, Delle Sedie A, Ferrari SM, Maccheroni M, Bombardieri S, Riente 
L, Ferrannini E. 2008d. High values of alpha (CXCL10) and beta (CCL2) circulating 
chemokines in patients with psoriatic arthritis, in presence or absence of autoimmune 
thyroiditis. Autoimmunity 41:537-542. 
Antonelli A, Ferri C, Ferrari SM, De Marco S, Di Domenicantonio A, Centanni M, 
Pupilli C, Villa E, Menichetti F, Fallahi P. 2010b. Interleukin-1β, C-x-C motif ligand 10, 
and interferon-gamma serum levels in mixed cryoglobulinemia with or without 
autoimmune thyroiditis. J Interferon Cytokine Res 30:835-842.  
Antonelli A, Ferri C, Fallahi P, Ferrari SM, Frascerra S, Pampana A, Panicucci E, Carpi 
A, Nicolini A, Ferrannini E. 2009d. CXCL10 and CCL2 chemokine serum levels in 
patients with hepatitis C associated with autoimmune thyroiditis. J Interferon Cytokine 
Res 29:345-351. 
 Antonelli A and others 
 
 17 
Bièche I, Asselah T, Laurendeau I, Vidaud D, Degot C, Paradis V, Bedossa P, Valla DC, 
Marcellin P, Vidaud M. 2005. Molecular profiling of early stage liver fibrosis in patients 
with chronic hepatitis C virus infection. Virology 332:130-144. 
Butera D, Marukian S, Iwamaye AE, Hembrador E, Chambers TJ, Di Bisceglie AM, 
Charles ED, Talal AH, Jacobson IM, Rice CM, Dustin LB. 2005. Plasma chemokine 
levels correlate with the outcome of antiviral therapy in patients with hepatitis C. Blood 
106:1175-1182. 
Diago M, Castellano G, Garcia-Samaniego J, Perez C, Fernandez I, Romero M, Iacono 
OL, Garcia-Monzon C. 2006. Association of pretreatment serum interferon gamma 
inducible protein 10 levels with sustained virological response to peginterferon plus 
ribavirin therapy in genotype 1 infected patients with chronic hepatitis C. Gut 55:374-
379.  
Domberg J, Liu C, Papewalis C, Pfleger C, Xu K, Willenberg HS, Hermsen D, 
Scherbaum WA, Schloot NC, Schott M. 2008. Circulating chemokines in patients with 
autoimmune thyroid diseases. Horm Metab Res 40:416-421. 
Ferri C, Zignego AL, Pileri SA. 2002. Cryoglobulins (review). J Clin Pathol 55: 4-13. 
Ferri C. 2008. Mixed cryoglobulinemia. Orphanet J Rare Dis 3:25. 
Ferri C, Monti M, La Civita L, Longombardo G, Greco F, Pasero G, Gentilini P, 
Bombardieri S, Zignego AL. 1993. Infection of peripheral blood mononuclear cells by 
hepatitis C virus in mixed cryoglobulinemia. Blood 82:3701–3704. 
Helbig KJ, Ruszkiewicz A, Lanford RE, Berzsenyi MD, Harley HA, McColl SR, Beard 
MR. 2009. Differential expression of the CXCR3 ligands in chronic hepatitis C virus 
(HCV) infection and their modulation by HCV in vitro. J Virol 83:836-846. 
 Antonelli A and others 
 
 18 
Kimura H, Kimura M, Rose NR, Caturegli P. 2004. Early chemokine expression induced 
by interferon-gamma in a murine model of Hashimoto's thyroiditis. Experimental and 
Mol Pathol 77:161-167. 
Lacotte S, Brun S, Muller S, Dumortier H. 2009. CXCR3, inflammation, and 
autoimmune diseases. Ann N Y Acad Sci 1173:310-317. 
Lagging M, Romero AI, Westin J, Norkrans G, Dhillon AP, Pawlotsky JM, Zeuzem S, 
von Wagner M, Negro F, Schalm SW, Haagmans BL, Ferrari C, Missale G, Neumann 
AU, Verheij-Hart E, Hellstrand K; DITTO-HCV Study Group. 2006. IP-10 predicts viral 
response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 
infection. Hepatology 44:1617-1625.  
Liao F, Rabin RL, Yannelli JR, Koniaris LG, Vanguri P, Farber JM. 1995. Human Mig 
chemokine: biochemical and functional characterization. J Exp Med 182:1301-1314. 
Loetscher P, Pellegrino A, Gong JH, Mattioli I, Loetscher M, Bardi G, Baggiolini M, 
Clark-Lewis I. 2001. The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, 
are natural antagonists for CCR3. J Biol Chem 276:2986-2991. 
Moura AS, Carmo RA, Teixeira AL, Leite VH, Rocha MO. 2010. Soluble inflammatory 
markers as predictors of liver histological changes in patients with chronic hepatitis C 
virus infection. Eur J Clin Microbiol Infect Dis 29:1153-1161. 
Wan L, Kung YJ, Lin YJ, Liao CC, Sheu JJ, Tsai Y, Lai HC, Peng CY, Tsai FJ. 2009.  
Th1 and Th2 cytokines are elevated in HCV-infected SVR(-) patients treated with 
interferon-alpha. Biochem Biophys Res Commun 379:855-860. 
Romero AI, Lagging M, Westin J, Dhillon AP, Dustin LB, Pawlotsky JM, Neumann AU, 
Ferrari C, Missale G, Haagmans BL, Schalm SW, Zeuzem S, Negro F, Verheij-Hart E, 
Hellstrand K; DITTO-HCV Study Group. 2006. Interferon (IFN)-gamma-inducible 
 Antonelli A and others 
 
 19 
protein-10: association with histological results, viral kinetics, and outcome during 
treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus 
infection. J Infect Dis 194:895-903.  
Wasmuth HE, Lammert F, Zaldivar MM, Weiskirchen R, Hellerbrand C, Scholten D, 
Berres ML, Zimmermann H, Streetz KL, Tacke F, Hillebrandt S, Schmitz P, Keppeler H, 
Berg T, Dahl E, Gassler N, Friedman SL, Trautwein C. 2009. Antifibrotic effects of 
CXCL9 and its receptor CXCR3 in livers of mice and humans. Gastroenterology 137: 
309-319, 319.e1-3. 
Zeremski M, Dimova R, Brown Q, Jacobson IM, Markatou M, Talal AH. 2009. 
Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis 
C virus infection. J Infect Dis 200:1774-1780.  
Zignego AL, Deny P, Feray O, Ponzetto A, Gentilini P, Tiollais P, Brechot C. 1990. 
Amplification of hepatitis delta virus RNA sequences by polymerase chain reation: a tool 
for viral detection and cloning. Mol Cell Probes 4:45–51. 
 
 
 Antonelli A and others 
 
 20 
Figure Legends 
 
Fig. 1. 1a. Patients with mixed cryoglobulinemia without autoimmune thyroiditis (MCo) 
have serum CXCL9 levels significantly (*) higher than control subjects without 
thyroiditis (Ctrl 1) (p<0.0001; ANOVA). 1b. Patients  with mixed cryoglobulinemia and 
thyroiditis (MC+AT) have serum CXCL9 levels significantly (*) higher than Control 2 
(Ctrl 2) (p<0.0001; ANOVA). The box indicates the lower and upper quartiles and the 
central line is the median value; the horizontal lines at the end of the vertical lines  are the 
2.5% and 97.5% values. 
 
Fig. 2. 2a. Patients with mixed cryoglobulinemia without autoimmune thyroiditis (MCo) 
have serum CXCL10 levels significantly (*) higher than control subjects without 
thyroiditis (Ctrl) (p<0.0001; ANOVA). 2b. Patients with mixed cryoglobulinemia and 
thyroiditis (MC+AT) have serum CXCL10 levels significantly (*) higher than Control 2 
(AT) (p<0.0001; ANOVA). The box indicates the lower and upper quartiles and the 
central line is the median value; the horizontal lines at the end of the vertical lines  are the 
2.5% and 97.5% values. 
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Table 1. Clinical characteristics of 60 patients with HCV-
related MC without autoimmune thyroiditis (MCo) and 35 
with autoimmune thyroiditis (MC-AT). No significant 
difference was observed about the undermentioned 
characteristics in the 2 groups.  
 MCo 
Without 
thyroiditis 
n=60 
MC-AT 
With  
thyroiditis  
n=35 
 
Age (years) 
 
63 ± 10    
 
60 ± 11   
Men/Women 13/47 9/26 
Disease duration with MC (years) 10 ± 11   9 ± 12    
Purpura/skin vasculitis 91% 87% 
Weakness 90% 94% 
Arthralgias 89% 95% 
Arthritis 15% 12% 
Raynaud's phenomenon 45% 47% 
Secondary Sjøgren's syndrome 46% 51% 
Peripheral neuropathy 67% 71% 
Renal involvement* 11% 14% 
Aminotransferases elevation and/or 
histologic activity† 
82% 78% 
Cryocrit (%)   4.1 ± 8.9   4.4 ± 9.4      
C3 (normal: 60-130 mg/dL) 79 ± 37    81 ± 34   
C4 (normal: 20-55 mg/dL) 11 ± 10      10 ± 12       
Antinuclear antibodies  
 
Antimitochondrial antibodies  
 
Anti-smooth muscle antibodies  
 
Anti-extractable nuclear antigen 
antibodies  
24% 
7% 
17% 
5% 
28% 
10% 
22% 
8% 
* Serum creatinine >1.5 mg/dL and/or proteinuria >0.5 gr/24h. 
† Increase of the liver enzyme ALT and/or histological alterations. 
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Table 2. Thyroid status of control subjects (Control 1), control autoimmune thyroiditis 
(Control 2), patients with cryoglobulinemia without (MC) or with autoimmune thyroiditis 
(MC-AT). 
 
 Controls 1 Controls 2 MC MC-AT p value 
 Healthy subjects  thyroiditis  
without 
thyroiditis 
with 
 thyroiditis   
No. 60 35 60 35  
      
Age (years) 61 ± 13 62 ± 12 63 ± 10 60 ± 11 ns 
      
Gender (M/F) 13/47  9/26 13/47 9/26 ns 
      
Thyroid volume (mL) 11 ± 10 12 ± 12 10 ± 12 11 ± 13 ns 
      
Hypoechoic (%) 0 82 0 85 0.0001 
      
Hypervascular (%) 0 45 0 43 0.0001 
      
Serum TSH (mcU/mL) 1.2 ± 0.8 2.0 ± 1.8 1.3 ± 0.9 3.0 ± 2.5* 0.001 
      
AbTPO (UI/mL) 9 ± 10 213 ± 435° 11 ± 7  163 ± 376° 0.0001 
      
AbTg (UI/mL) 11 ± 9 194 ± 371° 8 ± 11 234 ± 296° 0.0007 
      
TRAb (UI/mL) 0 0 0 0 <0.0001 
      
AbTPO positivity (%) 0 84 0 78 0.0001 
      
AbTg positivity (%) 0 79 0 69 0.0001 
      
Subclinical hypothyroidism 
(%) 0 6 0 24 0.002 
      
CXCL10 (pg/mL) 88 ± 50 154 ± 123§ 312 ± 168^ 393 ± 184* <0.0001 
      
CXCL9 (pg/mL) 72 ± 25 146 ± 88§ 382 ± 158^ 493 ± 214* <0.0001 
      
Antithyroperoxidase antibody = AbTPO 
Antithyroglobulin antibody = AbTg 
Thyroid-stimulating hormone = TSH 
Antithyrotropin-receptor antibody = TRAb 
* p<0.05 or less versus Control 1 or versus Control 2,  or versus MCo. 
° p<0.05 or less versus Control 1 and versus MCo. 
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§ p<0.05 or less versus Control 1. 
^ p<0.05 or less versus Control 1 or versus Control 2. 
Mean group values were compared by using one-way analysis of variance (ANOVA) for normally 
distributed variables, otherwise by the Mann-Whitney U or Kruskal-Wallis test. Post-hoc comparisons on 
normally distributed variables were carried out using the Bonferroni-Dunn test. Proportions were compared 
by the Chi-Square test. 
 
